Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty - PubMed (original) (raw)
Clinical Trial
. 1993 Mar-Apr;15(2):374-82.
Affiliations
- PMID: 8519045
Clinical Trial
Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty
M Setsuda et al. Clin Ther. 1993 Mar-Apr.
Abstract
The effect of probucol, a drug that inhibits the secretion of smooth muscle cell-derived growth factor, was evaluated in the prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA). In 67 patients who successfully underwent prospective PTCA for the first time, the effects obtained in 31 patients given 750 mg or 1000 mg of probucol daily (group P) were compared with those in 36 patients given 150 mg of dipyridamole daily (group D). Drug treatment was initiated at least 7 days before PTCA and was continued for 3 to 6 months after PTCA, at which time a follow-up angiography was performed. There were no significant differences in patient characteristics (age, sex, pre-PTCA severity of angina pectoris), the number of affected vessels undergoing dilatation, or the residual degree of stenosis. The restenosis rate was significantly lower in group P (6 cases, 19.4%) than in group D (15 cases, 41.7%). In the nonrestenosis subgroup, the degree of stenosis progressed from 28.0 +/- 13.9% just after PTCA to 32.4 +/- 20.5% at follow-up angiography in group P, while it progressed significantly from 28.6 +/- 15.6% to 40.1 +/- 21.2% in group D (P < 0.05). A significant drop in serum cholesterol was observed in group P. The restenosis rate was lower in patients with high cholesterol levels at PTCA. No adverse reactions were noted in any patient. We conclude that probucol is effective in preventing restenosis after PTCA.
Similar articles
- [The importance of serum lipid level for restenosis following initial successful percutaneous transluminal coronary angioplasty in patients with unstable angina].
Kishi K, Hiasa Y, Tanaka H, Tanimoto M, Kinoshita M, Shinohara A, Wada T, Aihara T. Kishi K, et al. J Cardiol. 1996 Aug;28(2):79-84. J Cardiol. 1996. PMID: 8814525 Japanese. - [Reduction in the rates of restenosis after coronary angioplasty with simvastatin and probucol].
Merchán Herrera A, López Mínguez JR, Alonso Ruiz F, Escola JM, Címbora Ortega A, Poblador Curto MA, Redondo Méndez A, Romero Santisteban R, Geniz Gallardo I, González Fernández R, Millán Núñez V. Merchán Herrera A, et al. Rev Esp Cardiol. 1999 Oct;52(10):778-84. Rev Esp Cardiol. 1999. PMID: 10563153 Spanish. - Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
Schwartz L, Bourassa MG, Lespérance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Schwartz L, et al. N Engl J Med. 1988 Jun 30;318(26):1714-9. doi: 10.1056/NEJM198806303182603. N Engl J Med. 1988. PMID: 2967433 Clinical Trial. - Prevention of restenosis after PTCA: role of calcium antagonists.
Hoberg E, Kübler W. Hoberg E, et al. J Cardiovasc Pharmacol. 1991;18 Suppl 6:S15-9. J Cardiovasc Pharmacol. 1991. PMID: 1725911 Review. - [Anti-atherogenic drugs].
Kanaki T, Saito Y. Kanaki T, et al. Nihon Rinsho. 1998 Oct;56(10):2635-9. Nihon Rinsho. 1998. PMID: 9796331 Review. Japanese.
Cited by
- Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.
Yamashita S, Masuda D, Ohama T, Arai H, Bujo H, Kagimura T, Kita T, Matsuzaki M, Saito Y, Fukushima M, Matsuzawa Y; PROSPECTIVE Study Group. Yamashita S, et al. J Atheroscler Thromb. 2016 Jun 1;23(6):746-56. doi: 10.5551/jat.32813. Epub 2016 Jan 22. J Atheroscler Thromb. 2016. PMID: 26803913 Free PMC article. Clinical Trial. - Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis.
Liu J, Li M, Lu H, Qiao W, Xi D, Luo T, Xiong H, Guo Z. Liu J, et al. PLoS One. 2015 Apr 21;10(4):e0124021. doi: 10.1371/journal.pone.0124021. eCollection 2015. PLoS One. 2015. PMID: 25898372 Free PMC article. Review. - Antioxidants: the good, the bad and the ugly.
Tardif JC. Tardif JC. Can J Cardiol. 2006 Feb;22 Suppl B(Suppl B):61B-65B. doi: 10.1016/s0828-282x(06)70988-6. Can J Cardiol. 2006. PMID: 16498514 Free PMC article. Review. - Antioxidants and atherosclerosis: emerging drug therapies.
Tardif JC. Tardif JC. Curr Atheroscler Rep. 2005 Feb;7(1):71-7. doi: 10.1007/s11883-005-0078-1. Curr Atheroscler Rep. 2005. PMID: 15683606 Review. - Current, new and future treatments in dyslipidaemia and atherosclerosis.
Chong PH, Bachenheimer BS. Chong PH, et al. Drugs. 2000 Jul;60(1):55-93. doi: 10.2165/00003495-200060010-00005. Drugs. 2000. PMID: 10929930 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources